1-Phenylcyclopentanecarboxylic acid | CAS:77-55-4

We serve 1-Phenylcyclopentanecarboxylic acid CAS:77-55-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1-Phenylcyclopentanecarboxylic acid

Chemical Name:1-Phenylcyclopentanecarboxylic acid
CAS.NO:77-55-4
Synonyms:1-Phenylcyclopentanecarboxylic acid
1-phenylcyclopentane-1-carboxylic acid
 
Physical and Chemical Properties:
Density 1.2±0.1 g/cm3
Boiling Point 338.8±21.0 °C at 760 mmHg
Melting Point 159-161 °C(lit.)
Molecular Formula C12H14O2
Molecular Weight 190.238
Flash Point 157.1±16.7 °C
Vapour Pressure 0.0±0.8 mmHg at 25°C
Index of Refraction 1.568
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Pentoxyverine(CAS:77-23-6).



Contact us for information like 1-Phenylcyclopentanecarboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-phenylcyclopentane-1-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-phenylcyclopentane-1-carboxylic acid Use and application,1-Phenylcyclopentanecarboxylic acid technical grade,usp/ep/jp grade.


Related News: In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.4-(4-AMINOPHENYL)MORPHOLIN-3-ONE manufacturer In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.1,1-Cyclohexanediacetic acid supplier Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.(R)-(+)-1-Boc-3-aminopyrrolidine vendor Citizens and residents will be allowed entry to New Zealand, but will be required to quarantine themselves for 14 days, Prime Minister Jacinda Ardern said.Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector.